Viatris Developed Markets — Finite-lived intangible assets, net decreased by 13.7% to $6.63B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 13.7%, from $7.68B to $6.63B. This decline may warrant attention — for this metric, higher values are generally preferred.
A steady or growing balance suggests ongoing investment in product pipelines, while a rapid decline may indicate asset aging or lack of replacement.
The net book value of identifiable intangible assets, such as patents, trademarks, and product rights, that have a defin...
Standard balance sheet item for pharmaceutical companies, often categorized as 'Intangible Assets' or 'Product Rights'.
vtrs_segment_developed_markets_finite_lived_intangible_assets_net| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $14.31B | $12.21B | $9.43B | $7.68B | $6.63B |
| QoQ Change | — | -14.7% | -22.8% | -18.6% | -13.7% |
| YoY Change | — | -14.7% | -22.8% | -18.6% | -13.7% |